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Breast cancer is the most prevalent malignancy in women. The success of breast cancer treatment relies on the
ability to detect the disease and correct molecular abnormalities at an early stage of disease development.
A recent article describes a marked decrease in the levels of ferroportin in breast cancer. More importantly, the pre-
sented results demonstrate convincingly the incredible diagnostic and prognostic value of ferroportin and hepcidin
gene expression in breast cancer and suggest that determination of these two molecular markers may be used as
guidance toward individualized therapy for breast cancer patients.
Background
Iron is essential for major fundamental cellular pro-
cesses in all living organisms. During recent years, inter-
est in the field of iron metabolism has been noticeably
expanding, driven by discovery of a variety of new mole-
cules involved in the functioning of iron metabolic path-
ways. Iron homeostasis in normal cells is accurately
balanced and tightly regulated by a coordinated func-
tioning of several systems that are responsible for the
uptake, intracellular storage, and removal of iron from
cells [1]; in cancer cells, however, this balance is fre-
quently and consistently compromised [2,3]. Several
recent reports have suggested that an association may
exist between altered intracellular iron homeostasis, per-
turbations in the functioning of proteins involved in the
iron-regulatory pathways, and breast cancer [4-8]. Thus
far, the conclusions have been conflicting and unconvin-
cing. The main question as to whether or not detection
of these abnormalities in iron-related metabolic path-
ways can be used as therapeutic targets for clinical man-
agement of breast cancer remains unresolved.
The article
I nar e c e n ti s s u eo fScience Translational Medicine,
researchers at Wake Forest University School of
Medicine demonstrated a critical role of ferroportin in
human breast cancer [9]. The authors reported a marked
decrease in the levels of ferroportin, the only known
mechanism responsible for the export of intracellular
non-heme-associated iron to date, in human breast can-
cer cell lines and breast cancer tissue. Down-regulation
of ferroportin was accompanied by up-regulation of hep-
cidin, which has emerged recently as the central regulator
of iron homeostasis in general, and as a key negative reg-
ulator of ferroportin in particular [10]. Hepcidin is a 25
amino acid liver-synthesized hormone that inhibits cellu-
lar efflux of iron by binding to ferroportin and causing its
subsequent degradation [10,11].
More importantly, the investigators showed that a
greater magnitude of ferroportin reduction was observed
in more aggressive breast cancer subtypes, and that low
ferroportin levels were significantly correlated with
other well-established prognostic markers for poor
breast cancer outcome, such as absence of estrogen
receptors, high histological grade, and spread of disease
to the lymph nodes. Based on these findings, Pinnix and
colleagues [9] determined that ferroportin expression
predicts the clinical outcome of breast cancer. The
obtained results demonstrate clearly that low ferroportin
gene expression was associated with poor breast cancer
prognosis, which was evidenced by a significant reduc-
tion in metastasis-free and disease-specific survival. In
contrast, high ferroportin expression was associated with
a better outcome, especially in a breast cancer patient
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low hepcidin expression. In this cohort of breast cancer
patients, 5-year and 10-year distant metastasis-free sur-
vival was 95% and 91%, respectively.
The viewpoint
Breast cancer is the most prevalent malignancy in
women. The success of breast cancer treatment relies
on the ability to detect the disease and correct molecu-
lar abnormalities at an early stage of disease develop-
ment. In this respect, the results of the study conducted
by Pinnix and coworkers are quite remarkable. First,
they demonstrated convincingly the incredible diagnos-
tic and prognostic value of ferroportin and hepcidin
gene expression in breast cancer. Additionally, they sug-
gested that determination of these two molecular mar-
kers may be used as guidance toward individualized
therapy for breast cancer patients, which is a foremost
goal of medicine in the 21st century.
Second, results of their study demonstrating that
increased concentrations of ferroportin inhibited growth
of cancer xenografts in mice open new targeted and
mechanism-based therapeutic approaches for breast can-
cer treatment. This is further supported by evidence that
breast cancer patients with a combination of high ferro-
portin and low hepcidin expression had extremely favor-
able prognosis for the disease outcome. Therefore,
therapeutic manipulations aimed to increase ferroportin
levels in breast cancer cells may substantially improve
the efficacy of breast treatment. Until now, most research
directed toward modulating aberrant iron homeostasis in
cancer cells has been focused on the development and
usage of specific iron chelators for treatment of cancer
[12]. However, targeted suppression of iron importer
genes - for example, transferrin receptors [8] - or
enforced expression of iron exporter genes - for example,
ferroportin [9] - offer a mechanism-based strategy for the
treatment of cancer, particularly for breast cancer [8,9].
Specifically, results of the study suggest that either direct
modulation of ferroportin levels or indirect modulation
of it through down-regulation of liver-specific hormone
hepcidin may be useful for the treatment of patients with
breast cancer. For instance, therapeutic strategies aimed
at hepcidin depletion by neutralizing antibodies, hepcidin
small interfering RNAs, microRNAs, or inhibitors of the
stimulatory pathways for hepcidin expression - for exam-
ple, CEBPa and/or CEBPb [13,14] - could be potential
candidates.
Although further studies are required to define the
mechanisms underlying the aberrant functioning of the
hepcidin-ferroportin pathway in breast cancer and to
determine how modulation of this pathway affects iron
homeostasis not only in cancer cells but also in normal
cells, the findings of Pinnix and colleagues could
facilitate the development of novel markers and thera-
peutic applications for breast cancer diagnosis and
treatment.
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